# Dyadic International Inc: overview DYAI · Nasdaq · CIK 1213809 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dyai.md) · [Financials](/companies/dyai/financials.md) · [Filings](/companies/dyai/filings.md) · [Insiders](/companies/dyai/insiders.md) Latest reported revenue: [$961.1k](/filings/0001493152-26-037258.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037258). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,958](/filings/0001493152-25-021908.md) | [817 d](/filings/0001493152-26-012672.md) | [394](/filings/0001493152-26-022722.md) | [967](/filings/0001493152-26-037258.md) | [1,165](/filings/0001493152-25-021908.md) | [566 d](/filings/0001493152-26-012672.md) | [1,111](/filings/0001493152-26-022722.md) | [961](/filings/0001493152-26-037258.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(10.4%)](/filings/0001493152-25-021908.md) | [(187.2%) d](/filings/0001493152-26-012672.md) | [(508.8%)](/filings/0001493152-26-022722.md) | [(178.9%)](/filings/0001493152-26-037258.md) | [(165.3%)](/filings/0001493152-25-021908.md) | [(271.6%) d](/filings/0001493152-26-012672.md) | [(171.3%)](/filings/0001493152-26-022722.md) | [(213.7%)](/filings/0001493152-26-037258.md) | | Net margin | % | [(10.4%)](/filings/0001493152-25-021908.md) | [(189.7%) d](/filings/0001493152-26-012672.md) | [(515.2%)](/filings/0001493152-26-037258.md) | [(185.6%)](/filings/0001493152-26-037258.md) | [(169.7%)](/filings/0001493152-25-021908.md) | [(277.1%) d](/filings/0001493152-26-012672.md) | [(175.9%)](/filings/0001493152-26-037258.md) | [(221.0%)](/filings/0001493152-26-037258.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-25-021908.md) | not reported | [(0.07)](/filings/0001493152-26-022722.md) | [(0.06)](/filings/0001493152-26-037258.md) | [(0.06)](/filings/0001493152-25-021908.md) | not reported | [(0.05)](/filings/0001493152-26-022722.md) | [(0.06)](/filings/0001493152-26-037258.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,404](/filings/0001437749-23-008425.md) | [2,930](/filings/0001437749-24-009857.md) | [2,899](/filings/0001437749-25-009350.md) | [3,495](/filings/0001493152-26-012672.md) | [3,090](/filings/0001493152-26-012672.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(612.7%)](/filings/0001437749-23-008425.md) | [(346.9%)](/filings/0001437749-24-009857.md) | [(283.9%)](/filings/0001437749-25-009350.md) | [(168.8%)](/filings/0001493152-26-012672.md) | [(232.8%)](/filings/0001493152-26-012672.md) | | Net margin | % | [(543.7%)](/filings/0001437749-23-008425.md) | [(332.2%)](/filings/0001437749-24-009857.md) | [(234.4%)](/filings/0001437749-25-009350.md) | [(166.2%)](/filings/0001493152-26-012672.md) | [(238.3%)](/filings/0001493152-26-012672.md) | | Diluted EPS | $ per share | [(0.47)](/filings/0001437749-22-007554.md) | not reported | not reported | [(0.20)](/filings/0001493152-26-012672.md) | [(0.23)](/filings/0001493152-26-012672.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dyai/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $831.7k | 928,233 | | Unchanged | | [CHAPIN DAVIS, INC.](/funds/872098.md) | 2026-06-30 | $795.7k | 888,004 | | Unchanged | | [Apis Capital Advisors, LLC](/funds/1386892.md) | 2026-06-30 | $721.2k | 804,882 | | Reduced −466,090 | | [TRUIST FINANCIAL CORP](/funds/92230.md) | 2026-06-30 | $292.3k | 326,200 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $224.9k | 250,905 | | Reduced −62,603 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $177.2k | 197,749 | | Reduced −77,676 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $125.0k | 139,478 | | Unchanged | | [MARATHON CAPITAL MANAGEMENT](/funds/1213206.md) | 2026-06-30 | $98.6k | 110,000 | | Unchanged | | [Sage Mountain Advisors LLC](/funds/1832274.md) | 2026-06-30 | $95.5k | 106,564 | | Unchanged | | [HighTower Advisors, LLC](/funds/1462245.md) | 2026-06-30 | $71.2k | 79,469 | | Unchanged | ## Recent filings [All 379 filings](/companies/dyai/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-25 | 21:27 ET | [8-K](/filings/0001493152-26-044398.md) | 3.01 Delisting notice | 0001493152-26-044398 | | 2026-09-11 | 21:28 ET | [S-1](/filings/0001493152-26-042435.md) | Registration statement | 0001493152-26-042435 | | 2026-08-14 | 13:17 ET | [8-K](/filings/0001493152-26-038039.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-038039 | | 2026-08-12 | 12:45 ET | [10-Q](/filings/0001493152-26-037258.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037258 | | 2026-08-12 | 12:45 ET | [8-K](/filings/0001493152-26-037257.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037257 | | 2026-07-24 | 12:00 ET | [8-K](/filings/0001493152-26-034475.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-034475 | | 2026-06-22 | 12:30 ET | [8-K](/filings/0001493152-26-029504.md) | 5.07 Shareholder vote results | 0001493152-26-029504 | | 2026-06-18 | 13:55 ET | [8-K](/filings/0001493152-26-029214.md) | 3.01 Delisting notice | 0001493152-26-029214 | | 2026-06-15 | 20:30 ET | [8-K](/filings/0001493152-26-028700.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028700 | | 2026-05-28 | 13:11 ET | [8-K](/filings/0001493152-26-025554.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-025554 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012672.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/382635f6-f3cb-47a6-99d5-26ac1070cc47) ## About the filer - CIK: 1213809 - Tickers: DYAI - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.